WallStreetZenWallStreetZen

NASDAQ: IPHA
Innate Pharma Sa Stock Forecast, Predictions & Price Target

OverviewForecast
EarningsRevenueDividendOwnership

Analyst price target for IPHA

Based on 1 analyst offering 12 month price targets for Innate Pharma Sa

Min Forecast
$11.00+480.47%
Avg Forecast
$11.00+480.47%
Max Forecast
$11.00+480.47%

Should I buy or sell IPHA stock?

Based on 1 analyst offering ratings for Innate Pharma Sa.

Buy
Strong Buy
0 analysts 0%
Buy
1 analysts 100%
Hold
0 analysts 0%
Sell
0 analysts 0%
Strong Sell
0 analysts 0%

Be the first to know when Wall Street analysts revise their IPHA stock forecasts and price targets.

IPHA stock forecasts by analyst

Analyst / FirmRatingActionPrice TargetUpside/DownsideDateAnalyst Color
lockedlocked$00.00+00.00%2025-04-24

1 of 1

Forecast return on equity

Is IPHA forecast to generate an efficient return?

Company
-91.86%
Industry
140.91%
Market
90.47%
IPHA's Return on Equity is... subscribe to Premium to read more.
Forecast High Return on Equity Forecast

Forecast return on assets

Is IPHA forecast to generate an efficient return on assets?

Company
-7.31%
Industry
32.45%
IPHA is forecast to generate... subscribe to Premium to read more.
Forecast Return on Assets vs Industry Forecast

IPHA earnings per share forecast

What is IPHA's earnings per share in the next 3 years based on estimates from 1 analyst?

Avg 1 year Forecast
-$0.82
Avg 2 year Forecast
-$0.81
Avg 3 year Forecast
-$0.65

IPHA revenue forecast

What is IPHA's revenue in the next 3 years based on estimates from 1 analyst?

Avg 1 year Forecast
$14.0M-33.2%
Avg 2 year Forecast
$7.3M-65.12%
Avg 3 year Forecast
$26.7M+27.15%
IPHA's revenue is forecast to... subscribe to Premium to read more.
Forecast High Revenue Growth Forecast

IPHA revenue growth forecast

How is IPHA forecast to perform vs Biotechnology companies and vs the US market?

Company
-0.81%
Industry
56.38%
Market
9.68%
IPHA's revenues are forecast to... subscribe to Premium to read more.
Forecast Revenue Growth vs Industry Forecast
IPHA's revenues are forecast to... subscribe to Premium to read more.
Forecast Revenue Growth vs Market Forecast

IPHA vs Biotech Stocks

TickerPricePrice TargetUp/downsideConsensus
IPHA$1.90$11.00+480.47%Buy
SPRO$2.83$5.00+76.68%Buy
VXRT$0.70$2.00+184.90%Strong Buy
ENTA$7.50$21.00+180.00%Buy
DMAC$3.65$10.00+173.97%Buy
View Top Biotech Stocks

Innate Pharma Sa Stock Forecast FAQ

Is Innate Pharma Sa Stock a good buy in 2025, according to Wall Street analysts?

The consensus among 1 Wall Street analyst covering (NASDAQ: IPHA) stock is to Buy IPHA stock.

Out of 1 analyst, 0 (0%) are recommending IPHA as a Strong Buy, 1 (100%) are recommending IPHA as a Buy, 0 (0%) are recommending IPHA as a Hold, 0 (0%) are recommending IPHA as a Sell, and 0 (0%) are recommending IPHA as a Strong Sell.

If you're new to stock investing, here's how to buy Innate Pharma Sa stock.

What is IPHA's earnings growth forecast for 2025-2027?

(NASDAQ: IPHA) Innate Pharma Sa's forecast annual earnings growth rate of N/A is not forecast to beat the US Biotechnology industry's average forecast earnings growth rate of 10.6%, and while it is not forecast to beat the US market's average forecast earnings growth rate of 15.33%.

Innate Pharma Sa's earnings in 2025 is -$56,217,045.On average, 1 Wall Street analyst forecast IPHA's earnings for 2025 to be -$68,740,876, with the lowest IPHA earnings forecast at -$68,740,876, and the highest IPHA earnings forecast at -$68,740,876. On average, 1 Wall Street analyst forecast IPHA's earnings for 2026 to be -$67,902,572, with the lowest IPHA earnings forecast at -$67,902,572, and the highest IPHA earnings forecast at -$67,902,572.

In 2027, IPHA is forecast to generate -$54,489,718 in earnings, with the lowest earnings forecast at -$54,489,718 and the highest earnings forecast at -$54,489,718.

What is IPHA's revenue growth forecast for 2025-2027?

(NASDAQ: IPHA) Innate Pharma Sa's forecast annual revenue growth rate of -0.81% is not forecast to beat the US Biotechnology industry's average forecast revenue growth rate of 56.38%, and while it is not forecast to beat the US market's average forecast revenue growth rate of 9.68%.

Innate Pharma Sa's revenue in 2025 is $22,864,772.On average, 1 Wall Street analysts forecast IPHA's revenue for 2025 to be $1,173,624,704, with the lowest IPHA revenue forecast at $1,173,624,704, and the highest IPHA revenue forecast at $1,173,624,704. On average, 1 Wall Street analysts forecast IPHA's revenue for 2026 to be $612,799,756, with the lowest IPHA revenue forecast at $612,799,756, and the highest IPHA revenue forecast at $612,799,756.

In 2027, IPHA is forecast to generate $2,234,078,454 in revenue, with the lowest revenue forecast at $2,234,078,454 and the highest revenue forecast at $2,234,078,454.

What is IPHA's forecast return on assets (ROA) for 2025-2028?

(NASDAQ: IPHA) forecast ROA is -7.31%, which is lower than the forecast US Biotechnology industry average of 32.45%.

What is IPHA's Price Target?

According to 1 Wall Street analyst that have issued a 1 year IPHA price target, the average IPHA price target is $11.00, with the highest IPHA stock price forecast at $11.00 and the lowest IPHA stock price forecast at $11.00.

The Wall Street analyst predicted that Innate Pharma Sa's share price could reach $11.00 by Apr 24, 2026. The average Innate Pharma Sa stock price prediction forecasts a potential upside of 480.47% from the current IPHA share price of $1.90.

What is IPHA's Earnings Per Share (EPS) forecast for 2025-2027?

(NASDAQ: IPHA) Innate Pharma Sa's current Earnings Per Share (EPS) is -$0.69. On average, analysts forecast that IPHA's EPS will be -$0.82 for 2025, with the lowest EPS forecast at -$0.82, and the highest EPS forecast at -$0.82. On average, analysts forecast that IPHA's EPS will be -$0.81 for 2026, with the lowest EPS forecast at -$0.81, and the highest EPS forecast at -$0.81. In 2027, IPHA's EPS is forecast to hit -$0.65 (min: -$0.65, max: -$0.65).

What is IPHA's forecast return on equity (ROE) for 2025-2028?

(NASDAQ: IPHA) forecast ROE is -91.86%, which is considered weak.
©2025 WallStreetZen
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsPerformanceHelp GuidesContactTwitterYouTubeNewsletter
Stock Tools
Top Performing AnalystsStock ScreenerStock ForecastTrending StocksStrong Buy StocksHighest Earnings StocksBest Dividend Paying StocksStatisticsStock Market SectorsStock Market IndustriesHow to Buy Stocks Online
Stock Ideas
Buy The DipBiggest Stock Gainers TodayBiggest Stock Losers Today52 Week High Stocks52 Week Low StocksMost Active Stocks TodayMost Undervalued StocksBest Penny Stocks to Buy NowBest Stocks Under $5Best Stocks Under $10
WallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.

Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.